Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy
| العنوان: | Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy |
|---|---|
| المؤلفون: | K. Latvala, Francesc Graus, Mikael Knip, Johanna Palmio, K. Savola, Ana Saiz, Jouko Isojarvi, Jukka Peltola, Petri Kulmala, Tapani Keränen |
| المصدر: | Neurology. 55:46-50 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2000. |
| سنة النشر: | 2000 |
| مصطلحات موضوعية: | Adult, Male, endocrine system, Adolescent, Glutamate decarboxylase, Drug Resistance, Radioligand Assay, Epilepsy, Cerebellum, medicine, Humans, Generalized epilepsy, Autoantibodies, Autoimmune disease, Type 1 diabetes, Cerebellar ataxia, Glutamate Decarboxylase, business.industry, Autoantibody, Middle Aged, medicine.disease, Immunohistochemistry, Immunology, Female, Neurology (clinical), Radiobinding assay, medicine.symptom, business |
| الوصف: | Background: Autoantibodies to glutamic acid decarboxylase (GAD-A) are present in type 1 diabetes and stiff man syndrome (SMS), and have also been reported in cerebellar ataxia. Epilepsy was present in 4 of 19 patients with SMS and GAD-A, implying that epilepsy sometimes is associated with anti-GAD autoimmunity.Methods: The authors investigated the prevalence of GAD-A in patients with therapy-resistant localization-related epilepsy (n = 51) and generalized epilepsy (n = 49) by a radiobinding assay. The positive samples were confirmed by immunohistochemistry and immunoblotting of recombinant human GAD65.Results: GAD-A were found in eight patients with localization-related epilepsy, whereas none of the patients with generalized epilepsy, other neurologic disorders (n = 38), or the control subjects (n = 48) had GAD-A. Two patients had high levels of GAD-A, similar to SMS, whereas six patients had significantly lower titers, characteristic of type 1 diabetes. The two patients with high levels of GAD-A had GAD-A both in serum and CSF by immunohistochemistry and immunoblotting. Both of them had longstanding therapy-resistant temporal lobe epilepsy but did not have diabetes. One had a history of autoimmune disease, whereas the other had serologic evidence of multiple autoantibodies without any clinical signs of autoimmune disease.Conclusions: GAD autoimmunity may be associated with refractory localization-related epilepsy. |
| تدمد: | 1526-632X 0028-3878 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d4f264de8d8456f2d9c1443147304eTest https://doi.org/10.1212/wnl.55.1.46Test |
| رقم الانضمام: | edsair.doi.dedup.....21d4f264de8d8456f2d9c1443147304e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1526632X 00283878 |
|---|